Your browser doesn't support javascript.
loading
EGFR activation limits the response of liver cancer to lenvatinib.
Jin, Haojie; Shi, Yaoping; Lv, Yuanyuan; Yuan, Shengxian; Ramirez, Christel F A; Lieftink, Cor; Wang, Liqin; Wang, Siying; Wang, Cun; Dias, Matheus Henrique; Jochems, Fleur; Yang, Yuan; Bosma, Astrid; Hijmans, E Marielle; de Groot, Marnix H P; Vegna, Serena; Cui, Dan; Zhou, Yangyang; Ling, Jing; Wang, Hui; Guo, Yuchen; Zheng, Xingling; Isima, Nikita; Wu, Haiqiu; Sun, Chong; Beijersbergen, Roderick L; Akkari, Leila; Zhou, Weiping; Zhai, Bo; Qin, Wenxin; Bernards, René.
Afiliação
  • Jin H; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shi Y; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lv Y; Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Yuan S; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Ramirez CFA; The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Lieftink C; Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wang L; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wang S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wang C; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Dias MH; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Jochems F; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Yang Y; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bosma A; The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Hijmans EM; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Groot MHP; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Vegna S; Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Cui D; Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Zhou Y; Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Ling J; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Wang H; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Guo Y; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zheng X; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Isima N; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Wu H; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Sun C; Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Beijersbergen RL; Division of Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Akkari L; Immune Regulation in Cancer Group, German Cancer Research Center, Heidelberg, Germany.
  • Zhou W; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Zhai B; Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Qin W; The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China. ehphwp@126.com.
  • Bernards R; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhaiboshi@sina.com.
Nature ; 595(7869): 730-734, 2021 07.
Article em En | MEDLINE | ID: mdl-34290403
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Quinolinas / Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Quinolinas / Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China